Figure 1.
Impact of karyotype on outcome in younger adults with AML. Overall survival is shown for adults with AML (median age 43 years, range 16–59) treated in successive Medical Research Council/National Cancer Research Institute trials (MRC AML10, AML12, AML15). A) Outcome of cytogenetic entities specified in the 2008 WHO classification3 B) Outcome of de novo, therapy-related and other secondary AML according to cytogenetic risk group (using revised MRC classification provided in Table 1) All patients with t(15;17) received an extended course of ATRA in addition to anthracycline-based chemotherapy.
